Picture loading failed.

Anti-IGF1R therapeutic antibody (Pre-made Figitumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Figitumumab (previously CP-751871) is a monoclonal antibody targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-213-1mg 1mg 3090
GMP-Bios-ab-213-10mg 10mg 21890
GMP-Bios-ab-213-100mg 100mg 148000
GMP-Bios-ab-213-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IGF1R therapeutic antibody (Pre-made Figitumumab biosimilar,Whole mAb)
INN Name Figitumumab
TargetIGF1R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesPfizer
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Colorectal cancer;Gastrointestinal cancer;Gynaecological cancer;Multiple myeloma;Non-small cell lung cancer;Prostate cancer;Rheumatoid arthritis;Sarcoma;Small cell lung cancer;Solid tumours
Development Techna